920 related articles for article (PubMed ID: 30003451)
1. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
2. Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.
Song H; Park JY; Kim JH; Shin TS; Hong SA; Huda MN; Kim BJ; Kim JG
J Korean Med Sci; 2022 Jul; 37(28):e220. PubMed ID: 35851862
[TBL] [Abstract][Full Text] [Related]
3. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
5. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.
Yoon C; Lu J; Kim BJ; Cho SJ; Kim JH; Moy RH; Ryeom SW; Yoon SS
J Gastrointest Surg; 2023 Apr; 27(4):666-676. PubMed ID: 36627466
[TBL] [Abstract][Full Text] [Related]
7. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology.
Dantes Z; Yen HY; Pfarr N; Winter C; Steiger K; Muckenhuber A; Hennig A; Lange S; Engleitner T; Öllinger R; Maresch R; Orben F; Heid I; Kaissis G; Shi K; Topping G; Stögbauer F; Wirth M; Peschke K; Papargyriou A; Rezaee-Oghazi M; Feldmann K; Schäfer AP; Ranjan R; Lubeseder-Martellato C; Stange DE; Welsch T; Martignoni M; Ceyhan GO; Friess H; Herner A; Liotta L; Treiber M; von Figura G; Abdelhafez M; Klare P; Schlag C; Algül H; Siveke J; Braren R; Weirich G; Weichert W; Saur D; Rad R; Schmid RM; Schneider G; Reichert M
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32614802
[TBL] [Abstract][Full Text] [Related]
8. Creation of EGD-Derived Gastric Cancer Organoids to Predict Treatment Responses.
McDonald HG; Harper MM; Hill K; Gao A; Solomon AL; Bailey CJ; Lin M; Barry-Hundeyin M; Cavnar MJ; Mardini SH; Pandalai PJ; Patel RA; Kolesar JM; Rueckert JA; Hookey L; Ropeleski M; Merchant SJ; Kim J; Gao M
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296998
[TBL] [Abstract][Full Text] [Related]
9. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
[TBL] [Abstract][Full Text] [Related]
11. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.
Li J; Xu H; Zhang L; Song L; Feng D; Peng X; Wu M; Zou Y; Wang B; Zhan L; Hua G; Zhan X
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2637-2647. PubMed ID: 31598791
[TBL] [Abstract][Full Text] [Related]
12. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
Hao X; Zu M; Ning J; Zhou X; Gong Y; Han X; Meng Q; Li D; Ding S
Phytother Res; 2023 Nov; 37(11):5315-5327. PubMed ID: 37469042
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
[TBL] [Abstract][Full Text] [Related]
17. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Schmäche T; Fohgrub J; Klimova A; Laaber K; Drukewitz S; Merboth F; Hennig A; Seidlitz T; Herbst F; Baenke F; Ada AM; Groß T; Wenzel C; Ball CR; Praetorius C; Schmidt T; Ringelband-Schilling B; Koschny R; Stenzinger A; Roeder I; Jaeger D; Zeissig S; Welsch T; Aust D; Glimm H; Folprecht G; Weitz J; Haag GM; Stange DE
Mol Cancer; 2024 Jan; 23(1):10. PubMed ID: 38200602
[TBL] [Abstract][Full Text] [Related]
18. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
19. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
